Advertisement

Journal of Pharmaceutical Innovation

, Volume 10, Issue 2, pp 130–139 | Cite as

Three Ply-Walled Microcapsules for Enhanced Pharmacokinetics of Poorly Absorbed Risedronate Sodium: Novel Stratagem Toward Osteoporosis

  • Purnima Rawat
  • Iqbal Ahmad
  • Divya Vohora
  • Farhan Jalees Ahmad
  • Sushama Talegaonkar
Research Article

Abstract

Effective and optimized drug delivery has always been one of the major challenge for the researchers in the last few decades and is still a very active field of research. The present investigation focuses on the development of a novel strategy to enhance the bioavailability of risedronate sodium which shows very poor and erratic absorption. A multiple emulsion technique has been used to prepare the three ply-walled microcapsules needed for targeting the specific sites. Box-Behnken model has been selected to optimize the effect of various process variables on particle size and entrapment efficiency. Optimized microcapsules (PN-F) were found to have a particle size of 3.97 ± 0.29 μm (PDI = 0.19 ± 0.09), entrapment efficiency of 79.12 ± 2.19 %, and maximum release of 96.34 ± 3.426 and 97.32 ± 2.486 % in simulated gastric and intestinal fluid, respectively, over the period of 24 h. In vivo pharmacokinetic study exhibits a substantial increase in the absolute bioavailability of the microcapsules (F = 40.68 ± 2.636 %) as compared to marketed formulation, RISOFOS®, CIPLA (F = 0.98 ± 0.086 %) (p < 0.01) leading to a more effective drug transport. A stability analysis has also been carried out and is found to be quite promising for the present formulation. The obtained outcomes strongly support the fact that the present formulation not only plays a vital role in the optimized delivery of risedronate sodium in osteoporosis management but also depicts negligible pitfalls.

Keywords

Risedronate sodium Bisphosphonates Microcapsules Osteoporosis Box-Behnken design 

Notes

Acknowledgments

The authors would like to thank the Indian Council of Medical Research for their financial support.

References

  1. 1.
    Malhotra N, Mithal A. Osteoporosis in Indians. Indian J Med Res. 2008;127(3):263–8.PubMedGoogle Scholar
  2. 2.
    Nordin BE. International patterns of osteoporosis. Clin Orthop Relat Res. 1966;45:17–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Cardoso L, Herman BC, Verborgt O, Laudier D, Majeska RJ, Schaffler MB. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res. 2009;24(4):597–605.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Negishi-Koga T, Takayanagi H. Bone cell communication factors and Semaphorins. Bonekey Rep. 2012;1:183.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Hayden JM, Mohan S, Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone. 1995;17(2 Suppl):93S–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Akesson K, Dreinhofer KE, Woolf AD. Improved education in musculoskeletal conditions is necessary for all doctors. Bull World Health Organ. 2003;81(9):677–83.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Neuprez A, Reginster JY. Bone-forming agents in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008;22(5):869–83.CrossRefPubMedGoogle Scholar
  9. 9.
    Hirabayashi H, Fujisaki J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin Pharmacokinet. 2003;42(15):1319–30.CrossRefPubMedGoogle Scholar
  10. 10.
    Ohno K, Mori K, Orita M, Takeuchi M. Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem. 2011;18(2):220–33.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev. 2000;42(3):175–95.CrossRefPubMedGoogle Scholar
  12. 12.
    Patashnik S, Rabinovich L, Golomb G. Preparation and evaluation of chitosan microspheres containing bisphosphonates. J Drug Target. 1997;4(6):371–80.CrossRefPubMedGoogle Scholar
  13. 13.
    Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Jia H-J, Li W, Zhao K. Determination of risedronate in rat plasma samples by ion-pair high-performance liquid chromatography with UV detector. Anal Chim Acta. 2006;562(2):171–5.CrossRefGoogle Scholar
  15. 15.
    Bhatnagar S, Nakhare S, Vyas SP. Poloxamer-coated three-ply-walled microcapsules for controlled delivery of diclofenac sodium. J Microencapsul. 1995;12(1):13–22.CrossRefPubMedGoogle Scholar
  16. 16.
    Zaghloul A, Vaithiyalingam S, Faltinek J, Reddy I, Khan M. Response surface methodology to obtain naproxen controlled release tablets from its microspheres with Eudragit L100-55. J Microencapsul. 2001;18(5):651–62.CrossRefPubMedGoogle Scholar
  17. 17.
    Ahmad N, Ahmad I, Umar S, Iqbal Z, Samim M, Ahmad FJ. PNIPAM nanoparticles for targeted and enhanced nose-to-brain delivery of curcuminoids: UPLC/ESI-Q-ToF-MS/MS-based pharmacokinetics and pharmacodynamic evaluation in cerebral ischemia model. Drug Deliv. 2014;1–20.Google Scholar
  18. 18.
    Elorza B, Elorza M, Sainz M, Chantres J. Comparison of particle size and encapsulation parameters of three liposomal preparations. J Microencapsul. 1993;10(2):237–48.CrossRefPubMedGoogle Scholar
  19. 19.
    Ahmad I, Akhter S, Ahmad MZ, Shamim M, Rizvi MA, Khar RK, et al. Collagen loaded nano-sized surfactant based dispersion for topical application: formulation development, characterization and safety study. Pharm Dev Technol. 2014;19(4):460–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Mirza MA, Agarwal SP, Rahman MA, Rauf A, Ahmad N, Alam A, et al. Role of humic acid on oral drug delivery of an antiepileptic drug. Drug Dev Ind Pharm. 2011;37(3):310–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Singh A, Ahmad I, Akhter S, Jain GK, Iqbal Z, Talegaonkar S, et al. Nanocarrier based formulation of Thymoquinone improves oral delivery: stability assessment, in vitro and in vivo studies. Colloids Surf B Biointerfaces. 2013;102:822–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Food, Drug Administration HHS. International Conference on Harmonisation; guidance on Q1A stability testing of new drug substances and products; availability. Notice. Fed Regist. 2001;66(216):56332–3.Google Scholar
  23. 23.
    Simanjuntak R, Setiawati E, Yunaidi DA, Handayani LR, Setiawati A, Utami BS, et al. Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers. Drug Res. 2014;64(3):136–40.Google Scholar
  24. 24.
    Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–33.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Purnima Rawat
    • 1
  • Iqbal Ahmad
    • 1
  • Divya Vohora
    • 2
  • Farhan Jalees Ahmad
    • 1
  • Sushama Talegaonkar
    • 1
  1. 1.Nanomedicine Research Laboratory, Department of Pharmaceutics, Faculty of PharmacyJamia HamdardNew DelhiIndia
  2. 2.Department of Pharmacology, Faculty of PharmacyJamia HamdardNew DelhiIndia

Personalised recommendations